Test

July 4, 2025 - WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East.

The GEMINI-NSCLC study generates a robust, multi-omic dataset for research in biomarker discovery. The study includes two patient cohorts:
- Patients diagnosed with Stage IV NSCLC receiving standard-of-care first-line checkpoint inhibitor therapy